Preoperative distinction between benign and malignant pelvic mass plays an important role in treatment planning ultimately based on the patient’s survival rate and quality of life.
The ROMA (Risk of Ovarian Malignancy Algorithm) predictor uses a combination of HE4 (Human Epididymis protein 4) and CA125 to assess the risk of ovarian epithelial cancer (EOC) in women with established pelvic mass.
It represents a useful algorithm with significant diagnostic value in detecting ovarian epithelial processes in postmenopausal women, but not in premenopausal patients.In addition, the very high specificity of HE4 in distinguishing endometriosis and benign ovarian cysts from EOC is emphasized.
As in the case of Ca 125 is not a clinical means of utilizing population control (screening test). Increased can be found in other clinical cases, a condition that requires thorough clinical laboratory testing and accurate differential diagnosis.
Aim of this study reflects the determination of usefulness of ROMA marker in the preoperative categorization of patients with ovarian processes at high and low risk for ovarian epithelial carcinoma (EOC).
Criteria for excluding these studies are established malignancy in both the minor pelvis and the systemic circulation, as well as the existence of systemic diseases.
Keywords: Epithelial ovarian cancer, Roma Index, Ca-125, HE4.